What is Sutro Biopharma's other commercial liabilities?

Sutro Biopharma (STRO) reported other commercial liabilities of $5.35M in Q1 2026.

How has Sutro Biopharma's other commercial liabilities changed year-over-year?

Sutro Biopharma's other commercial liabilities decreased by 53.7% year-over-year, from $11.55M to $5.35M.

What is the long-term trend for Sutro Biopharma's other commercial liabilities?

Over 5 years (2020 to 2025), Sutro Biopharma's other commercial liabilities has grown at a 10.7% compound annual growth rate (CAGR), from $8.82M to $14.64M.

Sutro Biopharma STRO Other Commercial Liabilities

Other Commercial Liabilities at other companies

Nuvectis Pharma, Inc.NVCT

——

XencorXNCR

——

AnaptysBio, Inc.ANAB

——

Roivant SciencesROIV

——

CytomX TherapeuticsCTMX

——

Recursion Pharmaceuticals, Inc.RXRX

——

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's other commercial liabilities?: Sutro Biopharma (STRO) reported other commercial liabilities of $5.35M in Q1 2026.
How has Sutro Biopharma's other commercial liabilities changed year-over-year?: Sutro Biopharma's other commercial liabilities decreased by 53.7% year-over-year, from $11.55M to $5.35M.
What is the long-term trend for Sutro Biopharma's other commercial liabilities?: Over 5 years (2020 to 2025), Sutro Biopharma's other commercial liabilities has grown at a 10.7% compound annual growth rate (CAGR), from $8.82M to $14.64M.